CODA Biotherapeutics, a biopharmaceutical company developing a gene therapy approach for the treatment of neurological diseases, announced the formation of a strategic partnership with the Facial Pain Research Foundation with the goal to identify and develop potential new therapies and cures for trigeminal neuralgia and related neuropathic pain.
More specifically, in the framework of this collaboration, the Facial Pain Research Foundation will support preclinical research of CODA’s chemogenetically controlled inhibitory ion channels in neuropathic pain.
Read more about CODA Biotherapeutics here.
Read more about Facial Pain Research Foundation here.
Image by Arek Socha from Pixabay.
